The present invention relates to monoclonal antibodies that bind or neutralize dengue type 1, 2, 3, and/or 4 virus. The invention provides such antibodies, fragments of such antibod
Bridgetown, Barbados;Abuja, Nigeria; Lisbon, Portugal; Gaborone, Botswana; Brasilia, Brazil; Bandar Seri Begawan, Brunei; Phnom Penh, Cambodia; Ottawa, Canada; Santiago, Chile; Beijing, China; Copenhagen, Denmark; Manila, Philippines; Kuwait City, Kuwait; Amman, Jordan; Riyadh, Saudi Arabia, etc...
Bridgetown, Barbados;Abuja, Nigeria; Lisbon, Portugal; Gaborone, Botswana; Brasilia, Brazil; Bandar Seri Begawan, Brunei; Phnom Penh, Cambodia; Ottawa, Canada; Santiago, Chile; Beijing, China; Copenhagen, Denmark; Manila, Philippines; Kuwait City, Kuwait; Amman, Jordan; Riyadh, Saudi Arabia, etc...
Bridgetown, Barbados;Abuja, Nigeria; Lisbon, Portugal; Gaborone, Botswana; Brasilia, Brazil; Bandar Seri Begawan, Brunei; Phnom Penh, Cambodia; Ottawa, Canada; Santiago, Chile; Beijing, China; Copenhagen, Denmark; Manila, Philippines; Kuwait City, Kuwait; Amman, Jordan; Riyadh, Saudi Arabia, etc...